Axiom Bio develops AI-powered predictive toxicology tools to help drug researchers identify liver toxicity early in development. Its platform uses a large proprietary dataset of over 115,000 small molecules screened on primary human liver cells, with imaging, biochemical readouts, pharmacokinetic data, and curated clinical outcomes to train models. The platform predicts hepatotoxicity and related pathways such as mitochondrial toxicity, ER stress, and ROS formation, providing mechanistic insights to guide decision-making. Its goal is to reduce time, cost, and risk in preclinical development by replacing costly animal tests with accurate, affordable in-silico predictions.
Company Size
11-50
Company Stage
Seed
Total Funding
$15M
Headquarters
San Francisco, California
Founded
2024
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?